Publications
239
Citations
2,960
Est. group size
—
Recurring co-author estimate
Active years
31
Publishing since 1996
Jingchuan Guo's research uses large-scale real-world health data to study the effects and safety of diabetes medications, especially GLP-1 receptor agonists and SGLT2 inhibitors, on outcomes like heart failure, dementia, depression, and cancer. This work often uses epidemiological and causal-inference methods (such as target trial emulation) applied to electronic health records and claims data, and also touches on health disparities and clinical decision-support tools. Note that a couple of listed publications (on cosmic rays and metal-organic framework materials) appear unrelated to this medical research focus and may reflect data mismatches.
Publication output has grown substantially over the last decade, rising from single digits in 2017-2020 to over 40-50 papers per year by 2024-2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Methodological Approaches to Real-World Evidence Generation for Glucagon-like Peptide-1–Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop
Annals of Internal Medicine · 2026
- Evidence of Cosmic-Ray Acceleration up to Sub-PeV Energies in the Supernova Remnant IC 443.
PubMed · 2026
- Consistency in causal reasoning for large language models in scenarios of HIV antiretroviral treatment, drug interactions, and side effects
npj Digital Medicine · 2026
- Risk of immune-related adverse events from checkpoint inhibitors in cancer patients with autoimmune disease: An emulated target trial.
Journal of Clinical Oncology · 2026
- GLP-1RA and SGLT2i Medications for Type 2 Diabetes and Alzheimer Disease and Related Dementias
JAMA Neurology · 2025
- Ni/N co-doped NH2-MIL-88(Fe) derived porous carbon as an efficient electrocatalyst for methanol and water co-electrolysis
Renewable Energy · 2025
- Efficacy and Safety of GLP-1 RAs in Children and Adolescents With Obesity or Type 2 Diabetes
JAMA Pediatrics · 2025
- Glucagon-Like Peptide-1 Receptor Agonists and Risk for Depression in Older Adults With Type 2 Diabetes
Annals of Internal Medicine · 2025
- GLP-1 RA Use and Survival Among Older Adults With Cancer and Type 2 Diabetes
JAMA Network Open · 2025
- Bimetallic FeNi-MOF@Al-foam metal composites for enhanced broadband noise reduction: sound absorption performance analysis and materials structural optimization
RSC Advances · 2025
- Advancing social determinants of health research and practice: Data, tools, and implementation
Journal of Clinical and Translational Science · 2025
- Optimizing Strategy for Lung Cancer Screening: From Risk Prediction to Clinical Decision Support
JCO Clinical Cancer Informatics · 2025
- GLP-1 Receptor Agonists and Research to Treat Overeating and Substance Use Disorders
Journal of Neuroscience · 2025
- Heterogeneous treatment effects of GLP‐1RAs and SGLT2is on risk of Alzheimer's disease and related dementia in patients with type 2 diabetes: Insights from a real‐world target trial emulation
Alzheimer s & Dementia · 2025
- Glycated hemoglobin and body mass index as mediators of GLP‐1RAs and Alzheimer's disease and related dementias in patients with type 2 diabetes
Alzheimer s & Dementia · 2025
- medRxiv×18
- Diabetes×12
- Diabetes Obesity and Metabolism×10
- Circulation×9
- Value in Health×9
- Kathleen Wyne
Medicine · The Ohio State University
- Pujing Zhao
Medicine · The Ohio State University
- Kieren J. Mather
Medicine · Indiana University
- Dipam Patel
Medicine · Purdue University West Lafayette
- Colleen Barclay
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 20, 2026.
Claim or correct this profile